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Aims:MicroRNAs (miRs) regulate processes involved in both cardiac remodeling and obesity. We investigated if
the expression of selected miRs in patients with heart failure (HF) is inﬂuenced by the presence of obesity.
Methods: In this case–control study, we compared plasma levels of miR-21, -130b, -221, -423-5p, and the -221/-
130b ratio in 57 age- andgender-matched subjects: 40HFpatients (20obeseHF and20 leanHF) and17 leanhealthy
controls. Body compositionwas estimated by bioelectrical impedance analysis.MiRsweremeasured by quantitative
reverse transcription-PCR. Bioinformatics analysis was performed based on miRs ﬁndings to predict their putative
targets and investigate their biological function.
Results: HF was associated with increased miR-423-5p levels in both lean and obese patients (P b 0.05 vs. controls)
without differences betweenHF groups.MiR-130b levelswere reduced in obeseHF patients comparedwithHF lean
(P=0.036) and controls (P=0.025).MiR-221 levelswere non-signiﬁcantly increased in obeseHF patients.MiR-21
levels were not different among the groups. MiR-221/-130b ratio was increased in obese HF patients, and was pos-
itively associatedwith body fat percentage (r=0.43; P=0.002), bodymass index (r=0.44; P=0.002), andwaist
circumference (r= 0.40; P= 0.020). Computational prediction of target genes followed by functional enrichment
analysis indicated a relevant role of miR-130b and miR-221 in modulating the expression of genes associated to
cardiovascular and endocrine diseases, and suggested their inﬂuence in important signaling mechanisms and in
numerous processes related to the circulatory and endocrine systems.
Conclusions: In HF patients, the presence of obesity is associated with a differential expression of selected miRs and
the miR-221/-130b ratio had signiﬁcant correlations with adiposity parameters. Computational target prediction
analysis identiﬁed several interrelated pathways targeted by miR-130b and miR-221 with a known relationship
with endocrine and cardiovascular diseases, representing potential mechanisms to be further validated.© 2015 Elsevier B.V. All rights reserved.LV, left ventricle; LVEF, left
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Both heart failure (HF) and obesity aremajor public health problems
worldwide that are associated with signiﬁcant mortality, morbidity and
healthcare expenditures (Roger, 2013; Cornier et al., 2011). Obesity is a
well-known risk factor for cardiovascular diseases and signiﬁcantly in-
creases the chance of developing HF (Oreopoulos et al., 2008). However,
overweight and obesity were also associated with lower all-cause and
cardiovascular mortality rates in HF patients (Oreopoulos et al., 2008;
Von Haehling et al., 2011), which has been termed the obesity paradox.
Themechanisms underlying this ﬁnding have been difﬁcult to ascertain.
MicroRNAs (miRs) are small non-coding endogenous RNAs that regu-
late gene expression at the post-transcriptional level by inhibiting transla-
tion or promoting the degradation of target mRNAs (Kumarswamy and
Thum, 2013). It has been conﬁrmed that extracellular mature miRs
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an attractive class of disease biomarkers (Creemers et al., 2012). The oc-
currence of miRs in the bloodstream may be due either to a cell mem-
brane disruption after an insult or to an active releasing process. Despite
theprocess involved,miRs are signalingmolecules that regulate processes
in distant or neighboring cells (Chen et al., 2012). Previous works have
demonstrated that miR-130b-enriched microvesicles can be transported
into adipocytes and downregulate protein peroxisome proliferator-
activated receptor-gamma (PPARG), inﬂuencing in the receptor
cell phenotype (Pan et al., 2014). Similarly, ﬁbroblast and endothelial-
derived microvesicle containing miRs were shown to target mRNA in
cardiomyocytes both in vitro and in vivo, inﬂuencing in molecular path-
ways related to inﬂammation and cell survival (Das and Halushka, 2015).
MiRswere shown to be implicated inmodulating various aspects re-
lated to cardiac remodeling (Topkara and Mann, 2011). Our group has
previously demonstrated that levels of miR-423-5p are elevated in the
coronary sinus of HF patients, suggesting that it has a cardiac origin
(Goldraich et al., 2014). Other miRs, such as miR-21 and miR-221,
have also been implicated in ventricular hypertrophy andHF pathogen-
esis (Tatsuguchi et al., 2007; Wang et al., 2012).
Circulating miRs have also been studied in obesity (Kilic et al., 2015;
Ortega et al., 2013), and are involved in obesity-related processes such
asdisruptionof fatty acidmetabolism, cellular hypertrophy, inﬂammation
and systemic insulin resistance (Alexander et al., 2011). Deregulation of
miRs expression was observed in the adipose tissue from obese patients,
such as lower levels of miR-130 and increased levels of miR-221, which
are associated with opposite changes in activation of major regulators of
adipogenesis (Lee et al., 2011; Meerson et al., 2013).
Therefore, the present case–control study aimed at comparing levels
of miR-21, miR-130b, miR-221, miR-423-5p, and the miR-221/-130b
ratio in blood samples from obese and lean patients with systolic HF
and in healthy lean subjects to investigate if the expression of miRs in
patients with HF is inﬂuenced by the presence of obesity. Through bio-
informatics analysis, we explored the potential role of differentially
expressed miRs in major cardiovascular, endocrine and cell signaling
pathways in order to shed light onpossiblemechanisms that link the ac-
tivity of these miRs with the obesity paradox.
2. Methods
2.1. Patients and controls
Patients were recruited at the Heart Failure and Transplant Clinic of
our institution. Subjectswith stable HF, 18 to 80 years old and a left ven-
tricular ejection fraction (LVEF) lower than 45% were included. Control
subjects were selected from donors at the Hemotherapy Center of our
institution. All controls underwent a focused clinical interview and
had no history of structural cardiac disease or HF symptoms.
Exclusion criteria for both controls and HF patients were cell dyscra-
sias, active inﬂammation, malignant disease and severe hepatic or renal
disease (creatinine N3mg/dl). Exclusion criteria for HF patients were as
follows: (1) episode of decompensation within the previous 30 days,
(2) acute coronary syndrome within the previous three months and
(3) presence of implantable devices such as pacemakers, implantable
cardioverter deﬁbrillators and cardiac resynchronization therapy-
deﬁbrillators, because theywere not eligible for bioelectrical impedance
analysis.
Obesity was deﬁned as body mass index (BMI) ≥30 kg/m2 and body
fat percentage N25% in men and N35% in women (Cornier et al., 2011),
measured by a bioimpedance analysis. Lean subjects were included if
BMI was b25 kg/m2 and body fat percentage was ≤22% in men and
≤32% in women (Pi-Sunyer, 2000).
Subjects were classiﬁed into three groups: (1) lean healthy controls,
(2) lean HF patients, and (3) obese HF patients. All groups were
matched for age and sex, and groups 2 and 3 were also matched
for LVEF, heart failure etiology (ischemic and non-ischemic), NewYork Heart Association (NYHA) class, use of beta-blockers and of
angiotensin-converter enzyme (ACE) inhibitor or angiotensin re-
ceptor blocker (ARB).
2.2. Data collection
Demographic data, clinical history, co-morbidities, echocardio-
graphic, electrocardiographic and laboratory data were collected. Body
mass index was calculated as weight in kilograms divided by squared
height in meters (kg/m2). Bioimpedance analysis was performed with
a tetrapolar bioimpedance equipment (Model 450, Tetrapolar, Biody-
namics, USA). Waist circumference for HF patients was measured by a
trained examiner and determined on the lesser curvature located be-
tween the ribs and the iliac crest after expiration.
2.3. Measurement of circulating miRs
Peripheral venous blood samples from all subjects were collected in
EDTA-coated tubes. Blood samples were centrifuged at 1500 rpm for
15 min at 4 °C within 1 h from collection and stored at −80 °C until
analysis.
Plasma samples were freeze–thawed and miR isolation was per-
formed using the commercially available mirVana PARIS Kit (Ambion,
Austin, TX, USA) using 495 μL of plasma. After protein denaturation,
50 pM (ﬁxed volume of 5 μL) of synthetic, non-human miR-39 from
Caenorhabditis elegans (cel-miR-39) (Qiagen, Valencia, CA, USA) was
spiked into plasma samples to control for potential technical variations
throughout the extraction and measurement procedures. Cel-miR-39
was simultaneously analyzed in the ﬁnal miR eluate, providing a stan-
dard control for the concentration of studied miRs obtained from sub-
ject samples.
The concentration of miRs was determined by spectrophotometric
analysis (NanoDrop 1000, Thermo Scientiﬁc, Wilmington, DE, USA).
Reverse transcription (RT) reactions were performed according to
manufacturer's instructions, using miRs Reverse Transcription Kit (Life
Technologies, Carlsbad, CA, USA). MicroRNAs of interest (miR-21,
-130b, -221 and -423-5p) were measured by quantitative RT-
polymerase chain reaction (qRT-PCR) using TaqMan® miRs Expression
Assays probes (Life Technologies) on the 7500 Real Time PCR System
(Life Technologies). All miR qRT-PCR reactions were run in triplicate,
and the relative expression values were determined using the 2−ΔΔCT
method, previously described in detail (Livak and Schmittgen, 2001).
2.4. Computational prediction of miR targets
A list of putative target genes was obtained for miRs differentially
expressed among the groups based on computational predictions from
the TargetScan algorithm (Lewis et al., 2005) (release 6.2; accessed
July 2014). TargetScan works by searchingmRNAs sites with high com-
plementarity to the seed region (nucleotides 2–7) of themiRs, assessing
sequence features derived from empirically deﬁned rules and site con-
servation across species. This bioinformatics analysis helps in the inter-
pretation of the biological andmolecular role ofmiRs (Bazil et al., 2014).
TargetScanwas speciﬁcally used because it is suggested to be one of the
most reliable miR target prediction algorithms available, presenting a
distinguished tradeoff between sensitivity and speciﬁcity (Sethupathy
et al., 2006; Baek et al., 2008; Alexiou et al., 2009). More importantly,
target prediction scores provided by TargetScan were shown to corre-
late with protein downregulation in a comparison between in vivo and
in silico ﬁndings (Baek et al., 2008).
As an attempt to evaluate the quality of TargetScan predictions, we
carried out a consensus analysis among several resources for gathering
miRNA-target interactions to investigate the extent to which predic-
tions by TargetScan are supported by other computational prediction
tools, as well as by experimentally validated data. It is likely that miR
targets predicted by different tools represent more solid hypotheses
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reasoning for this overlapping analysis. For this purpose, we collected
validated targets from miRTarBase (Hsu et al., 2010) and starBase (Li
et al., 2013) databases, and performed target prediction analysis with
Diana MicroT v4.0 (Maragkakis et al., 2009) and microRNA.org (August
release 2010) (Betel et al., 2008) tools. For starBase database, the search
was restricted for target sites predicted by two or more computer pro-
grams. FormicroRNA.org, we adopted the conservation criterion and re-
quired prediction scores less than or equal to−0.1 as computed by the
mirSVR algorithm (Betel et al., 2010).
2.5. Disease and functional enrichment analysis of predicted miR targets
To investigate if miR targets predicted by TargetScan are already as-
sociated with endocrine or cardiovascular disorders, we compiled a set
of known disease-related genes for the two pathological conditions of
interest in this study using information extracted from the Genetic
Association Database (GAD) (Becker et al., 2004) (update from April
2014; accessed July 2014) and Malacards database (Rappaport et al.,
2013) (version 1.05; accessed July 2014). For the GAD data, the query
was restricted for entries associated to diseases included in metabolic
or cardiovascular categories. For the Malacards database, disease-
associated gene sets were gathered using as search terms dilated cardio-
myopathy, hypertrophic cardiomyopathy,myocarditis, obesity andmorbid
obesity. A total of 824 genes were found for cardiovascular diseases and
2365 genes for metabolic and endocrine diseases using these two
sources.
Furthermore, to inspect the biological effects of the miRs of interest,
functional enrichment analysis of their putative target genes obtained
with TargetScan was conducted using the Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways database (release 70.0; accessed
July 2014) (Kanehisa and Goto, 2000). KEGG counts with 287 manually
curated biological pathways, divided into six general categories
(metabolism, genetic information processing, environmental information
processing, cellular processes, organismal systems and human diseases)
and several subcategories that range from speciﬁc disease types to pro-
cesses related to metabolism and basic cellular mechanisms. Terms as-
sociated to human diseases that are not related to cardiovascular,
endocrine or metabolic disorders were removed from this list. A total
of 221 KEGG terms were used for functional annotation of miR targets.
2.6. Identiﬁcation of disease-related miRs regulatory network
To better visualize the relationship among the differentially expressed
miRs and disease-related genes, we created a regulatory network that de-
picts potential interactions among miRs and their target genes and co-
regulators that are known to contribute for cardiovascular or endocrine
diseases (data gathered from GAD and Malacards database). The miR-
gene interactions correspond to TargetScan prediction data, experimen-
tally validated transcription factors (TF)-miR interactions were collected
from TransMir v1.2 (Wang et al., 2010) and TF-gene interactions derive
frommanually curated experimental data contained inHuman Transcrip-
tional Regulation Interactions database (HTRIdb) (Bovolenta et al., 2012).
Only relationships in which genes and TFs involved have a known associ-
ation with the pathological conditions of interest in our study were con-
sidered when mapping regulatory interactions. Cytoscape software
version 3.1.0 was used for graphical network visualization (Shannon
et al., 2003).
2.7. Ethical considerations
The study protocol was conducted according to the principles
outlined in the Declaration of Helsinki and was approved by the Ethics
Committee in Research of the Hospital de Clínicas de Porto Alegre.
Written informed consent was obtained from all subjects prior to inclu-
sion in the study.2.8. Statistical analysis
Normally distributed continuous variables are expressed asmean±
standard deviation, while non-normally distributed variables are
expressed as median and interquartile ranges. Categorical variables
are reported as absolute number and 25th–75th percentiles. MiR expres-
sion values are expressed as fold change relative to controls (control
values were set as 1). Plasma levels of miRs were compared by general-
ized estimating equation with Fisher's least signiﬁcant difference (LSD)
post hoc test. As discussed in literature (Levin et al., 1994), Fisher's LSD
has desirable properties when the number of groups is equal to three,
such as higher statistical power in relation to other multiple comparison
tests, which was shown to be substantial in practical standpoints, and
strong control of type I error rate. Differences between continuous vari-
ables were assessed using the Student t-test. The Chi-square test (or the
exact Fisher test) was used to compare categorical variables. Correlation
between plasma levels of miRs and other variables were determined
with the use of the Pearson correlation analysis after normalization of
non-Gaussian variables by log transformation. All statistical analyses
were performed with the use of SPSS statistical package (version 18.0)
for Windows (SPSS Inc., Chicago, IL) and a two-tailed P value b 0.05 was
considered statistically signiﬁcant.
Statistical analysis for functional annotation of miR targets was car-
ried outwith a hypergeometric test followed by false discovery rate cor-
rection (FDR; Benjamini–Hochberg procedure) using in-house scripts
based on the KEGG API and the R environment (R Development Core
Team, 2010). Aminimumof three genes from the list of putative targets
was required to be annotated in candidate KEGG pathways, and a
P value b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Clinical characteristics of HF patients and controls
A total of 40 HF patients (20 obese and 20 lean) and 17 control sub-
jects were enrolled in the study. Clinical and laboratory characteristics
of patients and controls are shown in Table 1.
According to group deﬁnitions, the expected differences in adiposity
parameters were observed in the obese HF group (body weight, BMI,
body fat percentage, and waist circumference). Both HF groups had se-
vere systolic dysfunction and mild functional limitation. Most patients
were under standard therapeutic regimen with beta-blockers and
angiotensin-converting enzyme inhibitors. There were no signiﬁcant
differences in clinical variables between both HF groups except for
hypertension.
3.2. MicroRNA expression levels
The expression levels of miR-130b (A), miR-221 (B), miR-423-5p
(C) and miR-21 (D) are depicted in Fig. 1. Levels of miR-130b were
not changed by the presence of HF (lean similar to controls), but they
were reduced in the presence of obesity (obese HF vs. lean HF patients
[P=0.036], obese HF patients vs. healthy controls [P=0.025]). In con-
trast, levels of miR-221 were increased only in the obese HF group, al-
though this difference was not statistically signiﬁcant. Regarding miR-
423-5p, both HF groups had higher levels compared with controls
(lean HF patients vs. controls [P=0.003], obese HF patients vs. controls
[P = 0.021]); and there was no difference between obese and lean HF
groups, reinforcing that thismiR is related to heart failure pathophysiol-
ogy. MiR-21 levels were not different among the groups in the post-hoc
analysis.
Due to the divergent changes observed in the expression proﬁles of
miR-130b andmiR-221 in obese HF patients, we also assessed and com-
pared the miR-221/-130b ratio expression among the groups, based on
previousworks that have adopted the concept ofmiRs ratios in the anal-
ysis ofmiRs differential expression (Larne et al., 2013; Fritz et al., 2014).
Table 1
Clinical and demographic characteristics of subjects.
Characteristic Healthy controls (n = 17) Lean HF (n = 20) Obese HF (n = 20)
Age (years) 52.1 ± 9.7 54.9 ± 10.7 54.9 ± 11.9
Male sex 12 (71) 13 (65) 13 (65)
White race 16 (94) 11 (55)a 14 (70)
Body weight (kg) 71.3 ± 11.5 61.0 ± 10.2 103.9 ± 20.5b
Body mass index (kg/m2) 24.7 ± 2.6 21.8 ± 2.1a 37.3 ± 5.1b
Body fat (%) 15.9 ± 5.4 15.7 ± 5.0 33.0 ± 5.5b
Waist circumference (cm) 84.8 ± 8.8 118.7 ± 11.9c
Heart rate (beats/min) 80.5 ± 13.5 80.3 ± 14.6
Echocardiography indices LVEF (%) 67.2 ± 3.3d 29.8 ± 7.4 29.8 ± 8.2
LVEDD (mm) 49.0 ± 3.9d 65.3 ± 9.1 65.9 ± 4.6
LVESD (mm) 30.2 ± 2.2d 55.7 ± 9.8 56.0 ± 5.0
NYHA class (%) I or I 17 (85) 17 (85)
III 3 (15) 3 (15)
HF etiology Ischemic 6 (30) 5 (25)
Non-ischemic 14 (70) 15 (75)
Medical history Hypertension 8 (40) 16 (80)e
Diabetes 6 (30) 8 (40)
Atrial ﬁbrillation or ﬂutter 4 (20) 8 (40)
Myocardial Infarction 4 (20) 4 (20)
Medication ACE inhibitor or ARB 19 (95) 19 (95)
Beta-blocker 16 (80) 16 (80)
Diuretic 14 (70) 17 (85)
MRA 7 (35) 14 (70)
Blood pressure (mm Hg) Systolic 120 (98–140) 135 (110–156)
Diastolic 70 (60–80) 80 (72–97)e
Laboratory Creatinine (mg/dl) 1.1 (0.8–1.2) 1.1 (0.9–1.4)
Hemoglobin (g/dl) 13.8 ± 1.2 13.6 ± 1.6
Total cholesterol (mg/dl) 160.2 ± 37.4 161.1 ± 32.0
LDL cholesterol (mg/dl) 89.2 ± 32.2 92.6 ± 33.4
HDL cholesterol (mg/dl) 41.2 ± 10.9 42.1 ± 10.2
Triglycerides (mg/dl) 148.2 ± 70.5 140.7 ± 70.0
Albumin (g/dl) 4.3 (3.8–4.5) 4.5 (4.2–4.6)
Data expressed asmean± standard deviation, number (%) ormedian (25th–75th percentile). ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; HDL, high density
lipoprotein; HF, heart failure; LDL, low density lipoprotein; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic
diameter; MRA, mineralocorticoid-receptor antagonist; and NYHA, New York Heart Association.
a P b 0.05 in comparison with controls.
b P b 0.001 in comparison with lean HF and with controls.
c P b 0.001 in comparison with lean HF.
d P b 0.001 in comparison with lean HF and with obese HF.
e P b 0.05 in comparison with lean HF.
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221/-130b ratio in the obese group (obese HF vs. lean HF patients
[P= 0.06], obese HF patients vs. healthy controls [P= 0.001]).
Furthermore, miR-221/-130b ratio levels were positively correlated
with bodymass index, body fat percentageweight, andwaist circumfer-
ence (Fig. 3). Individual values of miR-130b were inversely correlated
with body fat percentage (r =−0.27; P = 0.048) and had no correla-
tion to other obesity parameters. Other miRs had no correlation with
obesity and/or adiposity parameters. Expression levels of individual
miRs as well as the miR-221/-130b ratio did not correlate with tradi-
tional HF parameters such as LVEF, LV end-diastolic diameter or NYHA
functional class, except for a weak positive association between miR-
21 and NYHA class (P= 0.040) (P N 0.1 for all other comparisons).
3.3. Predicted targets of miR-130b and miR-221
Computational target prediction conducted with the TargetScan al-
gorithm (Lewis et al., 2005) identiﬁed 899 transcripts with conserved
sites (996 conserved and 241 poorly conserved sites) as putative targets
of miR-130b, and 446 transcripts with conserved sites (465 conserved
and 154 poorly conserved sites) to be potentially regulated by miR-
221. A total of 89 genes are common targets of both miRs, including
insulin-like growth factor 1 (IGF1), estrogen receptor 1 (ESR1), chemo-
kine (C–X–C Motif) Ligand 12 (CXCL12) and TIMPmetallopeptidase in-
hibitor 2 (TIMP2). Table S1 provides the complete list of miR targets
predicted by TargetScan.
Following TargetScan analysis, we obtained new lists of potential
targets for miR-130b and miR-221 from independent sources andperformed an overlapping analysis to investigate the degree of reliabil-
ity of predictions provided by TargetScan andwhich targets have stron-
ger evidence for biological relevance. We found 3156 potential targets
for miR-130b and 2558 for miR-221 using microRNA.org (Betel et al.,
2008), and 3698 putative targets for miR-130b and 2097 for miR-221
based on Diana MicroT v4.0 predictions (Maragkakis et al., 2009). Re-
garding experimental sources, we gathered a total of 7 validated targets
for miR-130b and 30 for miR-221 from miRTarBase (Hsu et al., 2010),
and 717 validated targets for miR-130b and 297 for miR-221 from
starBase (Li et al., 2013).
Results of this analysis are shown in Fig. 4 formiR-130b (A) andmiR-
221 (B), which depicts the Venn diagrams quantifying the similarities
and differences among the predictions obtained with the three algo-
rithms. We can observe that Diana MicroT and microRNA.org (with
scores estimated by mirSVR (Betel et al., 2010)) predicted a much
higher number of targets per miR compared to TargetScan, probably in-
creasing the false positive rate. Moreover, differently fromDianaMicroT
and microRNA.org, the great majority of putative targets retrieved
by TargetScan (i.e., 95.55% for miR-130b and 89.46% for miR-221) are
also supported by the prediction analysis carried outwith other compu-
tational resources. In addition, we found that TargetScan predictions
present signiﬁcantly higher overlap with validated targets from
miRTarBase and starBase than those obtained with Diana MicroT and
mirSVR scoring algorithms (Fig. 4-C). Speciﬁcally, 66.29% of miR-130b
targets and 44.84% of miR-221 targets found by TargetScan are covered
by starBase data, while the percentages computed for DianaMicroT and
miSVR predictions are in the 10–20% range, reinforcing the reliability of
TargetScan for this in silico analysis.
Fig. 1. Plasma levels of selected miRs in healthy controls, lean HF and obese HF patients. HF, heart failure. Expression levels of miR-130b (A), miR-221 (B), miR-423-5p (C) and miR-21
(D) are shown as mean ± standard error. Overall test P-values computed by the generalized estimating equations are reported for each miR. *P b 0.05, **P b 0.01 for group pairwise
comparisons.
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genes for miR-130b and 249 target genes for miR-221 (Fig. 4), repre-
sents a conserved set of putative targets to be used in experimental
analyses due to the stronger evidence for their role as functionally rele-
vant targets. Interestingly, the percentages of overlap with experimental
data increased in relation to those computed for TargetScan predictions
solely. Considering the targets commonly predicted by TargetScan,Fig. 2. Plasma levels of miR-221/-130b ratio in healthy controls, lean HF and obese HF
patients. HF, heart failure. MicroRNA levels are shown as mean ± standard error. Overall
test P-value was computed by the generalized estimating equations. *P b 0.05, **P b 0.01
for group pairwise comparisons.Diana MicroT and mirSVR for miR-130b and miR-221, we found that
72.72% and 54.21% of the genes, respectively, are included in the list of
validated targets retrieved from starBase. The list of targets obtained for
miR-130b and miR-221 based on the consensus analysis is provided in
Table S2.
Finally, we investigated if putative targets of miR-130b andmiR-221
have known associationwith cardiovascular or endocrine disorders. The
Venn diagramdepicted in Fig. 5 shows the overlap betweenmiR targets
predicted by TargetScan and disease-related genes obtained from the
GAD andMalacards database. Approximately 16.5% of miR-130b targets
and 16% of miR-221 targets participate in cardiovascular, metabolic or
endocrine disorders. These proportions are highly statistically signiﬁ-
cant (P b 10−5) according to permutation tests based on randomization
of subsets ofmiR targets used for comparison. The associations found for
cardiovascular and endocrine diseases are speciﬁed for the list of pre-
dicted targets given in Table S1.
3.4. Functional and network-based analysis of miR targets
Functional enrichment analysis of miR targets using pathway maps
from theKEGGdatabase helps to clarify the biological pathways affected
by miR-130b and miR-221, and consequently, to explore the biological
implications of their over- and under-expression. A total of 108 func-
tional KEGG terms were signiﬁcantly overrepresented in the putative
targets list (P b 0.05) (Fig. S1). Pathways involved in signaling mecha-
nisms for environmental information processing were highly representa-
tive formiR targets (21.3% of enriched terms), including the transforming
Fig. 3. Correlation graphs of miR-221/-130b ratio and adiposity parameters. MiR-221/-130b ratio correlates positively with bodymass index (A), body fat percentage (B), weight (C) and
waist circumference (D). Correlation coefﬁcients (r) and P-values are shown from Pearson analysis.
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inducible factor-1 (HIF-1), mammalian target of rapamycin (mTOR),
mitogen-activated protein kinase (MAPK) and phosphatidylinositol
3-kinase/protein kinase B (PI3K-Akt) signaling pathways.
As expected according to detectedmiRs expression levels, pathways
in cardiovascular diseases and endocrine diseases also stood out in this
analysis. Interestingly, many processes associated with the endocrineFig. 4. Consensus analysis carried out between TargetScan and other independent sources for m
(mirSVR scoring algorithm) formiR-130b (A) andmiR-221 (B), and compared to results obtaine
from miRTarBase and starBase databases (C) and the target overlap ratios were computed in rsystem (approximately 12% of annotated terms), such as the signaling
pathways by PPARG, adipocytokines, insulin and thyroid hormone, as
well as pathways related to the circulatory system (approximately 2%
of annotated terms), such as adrenergic signaling in cardiomyocytes
and vascular smooth muscle contraction, were found to be signiﬁcantly
targeted by the activity of both miRs. The ten most relevant enriched
pathways are given in Table 2.iR-target data. MiR target predictionwas performedwith DianaMicroT andmicroRNA.org
dwith TargetScan throughVenndiagrams. Experimentally validated targetswere collected
elation to predictions gathered from in silicomethods.
Fig. 5. Venn diagram showing the number of miR-130b and miR-221 targets associated
with endocrine and cardiovascular diseases. Disease-related genes were extracted from
GAD and Malacards database.
7J.G. Thomé et al. / Gene 574 (2015) 1–10A similarity analysis based on the Jaccard Coefﬁcient (JC)was carried
out among KEGG enriched terms (Fig. S2), which allows the identiﬁca-
tion of clusters of biological pathways that share a high overlap among
their annotated genes. Fig. 6 depicts the association map between eight
selected clusters that are semantically closer to the diseases of interest,
composed of a minimum of four KEGG terms. The node size is propor-
tional to the number of miR targets annotated in each KEGG term,
node color represents the (corrected) P-value for the enrichment anal-
ysis, and the edge width corresponds to the JC value for intra-cluster
and inter-cluster similarities.
Finally, a disease-related regulatory network indicated that
targets of miR-221 (A), miR-130b (B) and common miR targets
(C) share many regulatory relationships with MYC targets (F), and
are interconnected by a small group of transcription factors (D and
E) that plays a crucial role in network structural stability and communica-
tion (Fig. 7). In special, we identiﬁed V-ets avian erythroblastosis virus
E26 oncogene homolog 1 (ETS1), GATA Binding Protein 2 (GATA2) and
androgen receptor (AR) as important mediators between miR-130b and
miR-221 subnetworks, representing interesting targets to be further
experimentally validated.
4. Discussion
The main ﬁnding of the present study is that the presence of obesity
is associatedwith altered expression ofmiRs in patientswithHF. Specif-
ically, while the HF-related miR-423-5p was increased in both lean and
obese HF groups, miR-130b levels were not changed in lean HF patients
compared with controls, but were reduced in the obese HF group. In
contrast, miR-221 showed an overexpression tendency in obese versus
lean HF patients. Regarding the miR-221/-130b ratio, we found that it
was not only increased in the HF obese patients, but also correlated to
obesity/adiposity parameters.
The role of circulating miRs in HF has been previously explored
(Tijsen et al., 2010; Goren et al., 2012). Tijsen et al. elegantly exploredTable 2
Tenmost relevant KEGG biological pathways enriched for miR-130b andmiR-221 targets.
Pathway name Number of genes annotated Adjusted P-value
Endocytosis 32 4.214e-17
FoxO signaling pathway 24 8.289e-15
TGF-beta signaling pathway 19 1.256e-14
Wnt signaling pathway 24 2.407e-14
Estrogen signaling pathway 20 1.156e-13
Ras signaling pathway 29 3.188e-13
PI3K-Akt signaling pathway 36 4.985e-13
Focal adhesion 27 1.093e-12
Rap1 signaling pathway 27 2.221e-12
MAPK signaling pathway 29 8.036e-12
MAPK,mitogen-activated protein kinase; PI3K-Akt, phosphatidylinositol 3-kinase/protein
kinase B; and TGF-beta, transforming growth factor-beta.the diagnostic role of plasmamiRs in patients presenting with dyspnea.
MiR-423-5p demonstrated an excellent discriminatory ability to sepa-
rate HF patients from healthy controls and from non-HF cases of dys-
pnea (Tijsen et al., 2010). Recently, Goren and collaborators evaluated
186 circulating miRs in chronic systolic HF and controls. A miR-score,
based on cumulative levels of four miRs (including miR-423-5p), was
able to discriminate HF patients and controls with an overall accuracy
of 90% (Goren et al., 2012).We have recently demonstrated a signiﬁcant
difference in miR-423-5p transcoronary gradient in HF outpatients
compared with controls (Goldraich et al., 2014). In the present study,
we found a higher expression ofmiR-423-5p inHF patients, with no sig-
niﬁcant inﬂuence of obesity, reinforcing the concept that this particular
miR is a reliable biomarker of HF.
Obesity is also associated with changes in the miRs proﬁle (Kilic
et al., 2015; Ortega et al., 2013). MiR-21 is upregulated in human adi-
pose tissue in obesity and positively correlated with BMI (Keller et al.,
2011). Lee et al. found that adipose tissue from obese women contained
signiﬁcantly lower miR-130 and higher PPARG levels, and suggested
that miR-130 reduces adipogenesis by repressing PPARG biosynthesis
(Lee et al., 2011). MiR-221 was found to be upregulated in human sub-
cutaneous adipose tissue, and the expression levels of miR-221 were
positively correlated with BMI. In addition, miR-221 upregulated sever-
al proteins involved in fat metabolism, mimicking PPARG activation
(Meerson et al., 2013). Our analysis of putative target genes for miR-
130b and miR-221 corroborates these studies, revealing PPARG under
direct regulation of miR-130b and miR-221, having indirect inﬂuence
over proteins involved in energy production and fatty acid metabolism.
The miR-221/-130b ratio, relating two miRs with opposite changes
in expression levels for obese versus lean HF patients, was signiﬁcantly
increased in the obese HF group. The concept of miRs ratio has been
recently proposed to more precisely analyze the coordinated and
complementary action of expression regulation by miRs (Larne et al.,
2013), having as basis the known complexity and combinatorial
nature of genetic regulatory mechanisms (Balaga et al., 2012).
Previous works have adopted MiRs ratios and scores for data analysis
in distinct scenarios (Larne et al., 2013; Fritz et al., 2014), and
discussed advantages such as increased discrimination, speciﬁcity and
robustness, which make them especially attractive in clinical settings
(Fritz et al., 2014). Interestingly, themiR-221/-130b ratio also correlated
positively with BMI, percentage of body fat, weight and waist
circumference.
Bioinformatics analysis allows us to further explore the regulatory
mechanisms of miR-130b and miR-221 and raise hypotheses about
genes and pathways under strong inﬂuence of their activity. Computa-
tional target gene prediction followed by functional enrichment analysis
using KEGG database revealed an important role of miR-130b and miR-
221 in signal transduction processes. Among the most statistically signif-
icant enriched terms formiR targets,we found several signaling pathways
that play a crucial role in cell growth and proliferation, cardiovascular
development, cardiac hypertrophy and remodeling, and formation of
adipose tissue. FoxO signaling pathway, for instance, plays different
roles in vascular and cardiac development,modulating apoptosis, autoph-
agy, oxidative stress and angiogenesis (Ronnebaum and Patterson, 2010;
Gross et al., 2008). The FoxO family of transcription factors is essential in
preventing Akt-mediated cardiac hypertrophy and also regulates
cardiomyocyte differentiation (Ronnebaum and Patterson, 2010). On
the other hand, FoxO proteins, especially FoxO1, are important targets
of insulin action and regulate body energymetabolism and the formation
of skeletal muscle and adipose tissue through adipocyte differentiation
and myocyte/myotube formation (Gross et al., 2008).
TGF-beta andWnt signaling pathways were also overrepresented in
our functional enrichment analysis. TGF-beta plays an important role in
the infarcted and remodeling heart through its signaling cascade (Bujak
and Frangogiannis, 2007), while Wnt activity modulates the morpho-
genesis of the heart (Cohen et al., 2008). In addition, Wnt signaling is
also involved in adipogenesis, pancreatic B-cell function and type 2
Fig. 6. Associationmap among eight selected clusters, with at least four KEGG terms, that are semantically closer to the diseases of interest. Node size is proportional to the number of miR
targets annotated in each pathway, node color represents the (corrected) P-value, and edge width corresponds to the JC value for intra-cluster and inter-cluster similarities.
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miR-221were also found to target genes in the Ras and PI3K-Akt signal-
ing pathways, which have been implicated in cardiac hypertrophy, reg-
ulatingmRNA translation and cell growth through interactionswith the
mTOR pathway (Proud, 2004). Moreover, the leptin-associated PI3K
pathway, alongwith the extracellular signal-regulated kinase (ERK) sig-
naling cascades, seems to be important in cardiomyocyte proliferation
and protecting cardiac tissue from ischemia/reperfusion injury (Yang
and Barouch, 2007).
Previous studies have discussed the role of Rap1 and MAPK signaling
pathways, also found to be signiﬁcantly affected by miR-130b and miR-
221, in cell differentiation, proliferation and other cellular functions that
contribute to vascular pathologies (Jeyaraja et al., 2011; Musling, 2008).
Rap1 signaling is associatedwith the activation of hypertrophic pathways
and is emerging as a potential regulator of signiﬁcant processes in the car-
diovascular system(Jeyaraja et al., 2011).MAPKpromotes cardiac remod-
eling (Musling, 2008), but its activation is also known to have detrimental
effects in obesity and diabetes (Gehart et al., 2010).
Clustering of biological pathways based on JC similarity (Fig. 6) re-
sulted in a cluster composed exclusively of cardiovascular diseases
and related cellular processes (cluster 7). A high overlap was observedbetween clusters 7 and 19, as well as between clusters 20 and 19,
which encompass several signaling pathways that ﬁgure among the
most signiﬁcantly enriched terms (Table 2).
Disease-related regulatory network analysis identiﬁed a small num-
ber of transcription factors, in particular ETS1, GATA2 and AR, which
might be critical to establish, stabilize and allow the interplay of a com-
plex network of target genes. Based on experimentally veriﬁed TF-gene
interactions retrieved from HTRIdb (Bovolenta et al., 2012), we identi-
ﬁed relationships among these TFs and several genes that have been al-
ready associated with cardiovascular or endocrine diseases. GATA2 and
AR were both found to regulate leptin receptor (LEPR), beta-2 adrener-
gic receptor (ADRB2) and PPARG, while GATA2 also modulates leptin
(LEP) expression, thus inﬂuencing in the activity of genes involved in
energy balance, adipocyte differentiation and othermechanisms under-
lying endocrine disorders (Enns et al., 2011; Takenaka et al., 2012).
Genes implicated in the physiopathology of cardiovascular diseases
were also found as targets of these TFs. ETS1, GATA2 and AR modulate
the activity of vinculin (VCL), which has been previously associated
with dilated cardiomyopathy (Maeda et al., 1997;Wenet al., 2012). Fur-
thermore, we found that GATA2 is a regulator of NPPB, which encodes
BNP, a well-established clinical biomarker for decompensated heart
Fig. 7.Mir-130b and -221 disease-related regulatory network. The potential interactions amongmiR-130b and -221 with target genes and co-regulators that are associated to cardiovas-
cular and endocrine diseases are shown in this regulatory network. Different node types (i.e., miR, gene or TF) are speciﬁed by the node shape, and the node size is proportional to the
number of outgoing edges emanating from a node, i.e., the number of regulatory interactions exerted by each node. Targets of miR-221 (A), miR-130b (B) and common miR targets
(C) share many regulatory relationships with MYC targets (F), and are interconnected by a small group of TFs (D and E).
9J.G. Thomé et al. / Gene 574 (2015) 1–10failure (Vodovar et al., 2014). Hence, these transcription factors may
represent interesting elements for further experimental investigation
to help elucidate the action of miR-130b and miR-221.
All these ﬁndings, taken together, suggest a signiﬁcant interplay
among these pathways and a promising association of their activity
with the physiopathology of obesity and HF. Some potential limitations
of our study deserve consideration. Our analysis was based on a selected
number of miRs in a small group of controls and HF patients. However,
study subjects were highly selected to allow adequate matching for
baseline clinical characteristics (age, gender, LVEF, HF etiology, func-
tional class). Identiﬁcation of miR target genes based on bioinformatics
tools is an interesting approach that uses algorithms and computational
analysis to circumvent the costs and time limitation of performing this
task with experimental techniques. In general, the use of miR targets
prediction software that consider site conservation across species,
such as TargetScan, is associated with high precision and sensitivity
(Witkos et al., 2011). Comparison between in vivo results and in silico
predictions provided by several computational methods has revealed
that TargetScan is one of the best available algorithms and that the
scores associated with predicted interactions correlated with protein
downregulation, justifying our choice for this prediction tool (Baek
et al., 2008). We showed that a high proportion of putative targets
found by TargetScan have also support from other computational re-
sources, and that TargetScan presented the most expressive overlap
with experimentally validated data among the three in silicomethods
used (Fig. 4), reinforcing the distinguished performance of this tool. Weacknowledge, however, that validation studies are necessary and most
of these ﬁndings are hypothesis generators. The overlapping set of puta-
tive targets obtained by TargetScan, DianaMicroT andmicroRNA.org rep-
resents a more conserved set of predictions related to the action of miR-
130b andmiR-221, and its use is recommended in the process of prioritiz-
ing genes for further analyses. Alternatively, the compiled information
about gene-disease associations could be taken into consideration in the
selection of putative miR targets for experimental validation.
To our knowledge, this study provides the ﬁrst evidence that circulat-
ing miRs are deregulated in obese patients with HF, and we hypothesize
this deregulation might be contributing to the yet unexplained paradox
of obesity inHF. Computational target prediction analysis indicated an im-
portant role of these miRs in regulating cardiovascular and endocrine
diseases-related genes, and revealed signaling pathways associated to
the pathophysiology of obesity and HF that are modulated by both miR-
221 andmiR-130b. Further studies are needed to experimentally investi-
gate and validate these ﬁndings, hopefully shedding light in the cellular
mechanisms that are involved in the obesity paradox and resulting in
new therapeutic approaches for different groups of HF patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gene.2015.07.068.
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